TB-500 vs GHK-Cu
TB-500 is the synthetic Ac-LKKTETQ fragment marketed as an analogue of thymosin beta-4, a 43-amino-acid endogenous actin-sequestering peptide with a large preclinical literature on tissue repair. GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, an endogenous human plasma tripeptide that binds copper with high affinity and appears in cosmetic formulations as copper tripeptide-1. The two are habitually paired in recovery and skin-repair material because both are described as promoting angiogenesis and extracellular-matrix remodelling, and neither has an approved product for that use. No published study has administered both, or set one against the other in the same experiment, in any species or model. What does exist is a cluster of recent reviews, most published in 2026 across orthopaedic, sports medicine, pain medicine, gerontology and aesthetic journals, that name and describe both peptides side by side without testing either. Those reviews are the whole of the literature that engages the pair, and their recurring conclusion is that human evidence for both remains thin.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No experiment has administered thymosin beta-4 or TB-500 and GHK-Cu to the same subjects, and none has compared them against each other in cell culture, in animals or in people. Searches of PubMed and Europe PMC returned no comparative study; every located record that engages both is a review. Those reviews assemble the two peptides into a single category of regenerative or wound-healing peptides and then describe each separately. A 2026 narrative review in a pain medicine journal covered collagen peptides, BPC-157, thymosin beta-4, TB-500, GHK-Cu, growth hormone-related peptides and cibinetide in one framework of proposed mechanisms, evidence and regulatory status. A PRISMA-guided scoping review in a sports medicine journal screened the musculoskeletal literature for six peptides including TB-500 and GHK-Cu and reported that two thirds of the identified publications used preclinical animal models. A narrative review written for orthopaedic and sports medicine physicians stated that thymosin beta-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models while human orthopaedic data are lacking, and that GHK-Cu showed promise in wound healing and anti-inflammatory effects but that no clinical data support its use for musculoskeletal conditions. Comparison between the two therefore rests entirely on separate literatures using different cells, tissues, species and endpoints.
The 9 publications that cover both
- 01Review2026
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management
Luansritisakul C, et al. · Curr Pain Headache Rep · narrative review of regenerative peptides relevant to chronic pain, covering collagen peptides, BPC-157, thymosin beta-4, TB-500, GHK-Cu, growth hormone-related peptides and cibinetide
The review placed thymosin beta-4 and TB-500 alongside GHK-Cu in one account of regenerative peptides, summarising proposed mechanisms, preclinical and clinical evidence, safety profiles and regulatory status for each. The authors stated that most of these therapies remain unapproved by the US Food and Drug Administration and that clinical evidence in humans is limited. Neither peptide was administered.
- 02Systematic review2026
Peptide Supplements and Their Therapeutic Applications in Sports Medicine
Tewari K, et al. · Am J Sports Med · PRISMA-guided scoping review of PubMed; six peptides including TB-500 and GHK-Cu combined with musculoskeletal tissue terms, screened independently by two reviewers with a third as tiebreaker
Sixty-seven percent of the identified publications used preclinical animal models, most commonly rats, and each compound showed promising but variable effects on tendon, muscle, bone and ligament healing. Human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous designs. The authors concluded that the claimed musculoskeletal benefits of these peptide supplements remain unsubstantiated by current human trials.
- 03Review2026
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield CK, et al. · Am J Sports Med · narrative review of injectable peptide therapy; key peptides evaluated were BPC-157, thymosin beta-4, TB-500, CJC-1295 with ipamorelin, tesamorelin and GHK-Cu
The authors reported that thymosin beta-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, that human orthopaedic data are lacking and that both remain banned substances in sport. They reported separately that GHK-Cu showed promise in wound healing and anti-inflammatory effects but that no clinical data support its use for musculoskeletal conditions. This is the closest the literature comes to placing the two side by side on the same question.
- 04Review2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, Awan TM · Sports Med · narrative review of approved and unapproved peptides marketed direct to patients, including AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, thymosin beta-4 and TB-500
The review set out pharmacological mechanisms, safety profiles and regulatory status for each peptide and described a gray market of unapproved compounds operating largely outside regulatory oversight. It reported that many unapproved peptides show favourable tissue repair and metabolic outcomes in animal models while rigorous human safety data are scarce, and discussed the placebo effect and social media amplification as mediators of perceived efficacy.
- 05Review2026
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman OF, et al. · J Am Acad Orthop Surg Glob Res Rev · narrative review integrating mechanistic signalling data with orthopaedic relevance across wound-healing peptides, growth hormone secretagogues, recovery-enhancing agents and neuroactive peptides
The review grouped BPC-157, TB-500 and GHK-Cu together as wound-healing peptides described as promoting angiogenesis, integrin-mediated extracellular matrix remodelling and fibroblast activation. The authors stated that although preclinical studies are promising there is a current lack of clinical trials across the peptides reviewed.
- 06Review2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Renke G, Chinellato L · Int J Mol Sci · narrative review of therapeutic peptides across aesthetic, metabolic and endocrine use, including a healing and regeneration group covering BPC-157, thymosin beta-4 (TB-500), thymosin alpha-1 and GHK-Cu
The review assigned thymosin beta-4 and GHK-Cu to a single class of peptides described as promoting healing and tissue regeneration and modulating inflammation, listing improved skin and corneal healing and skin anti-aging action among the described targets. It noted that GHK-Cu is formulated topically for local action, and concluded that further studies are needed before most of the newer peptides can be used safely in humans.
- 07Review2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging
Mavrych V, et al. · Front Aging · narrative review with systematic searches of PubMed, Scopus and regulatory databases from inception through January 2026; nine peptides retained from 20 selected primary sources
GHK-Cu was categorised under dermal regeneration and TB-500 under tissue repair within a single review of nine peptides relevant to aging. The authors reported that non-approved peptides showed promising preclinical and limited clinical evidence but lack long-term safety data and systematic validation, and identified dosing, combination effects and monitoring biomarkers as open knowledge gaps.
- 08Review2026
Peptide-Based Approaches for Pain Relief and Healing in Wounds
Kołodyńska K, et al. · Int J Mol Sci · narrative review of topically applied peptides with analgesic, anti-inflammatory and regenerative activity for painful and chronic wounds
The review summarised separate primary work on each peptide. For GHK-Cu it reported that a liposomal complex applied to burn wounds in mice promoted angiogenesis and shortened healing time, and that GHK-Cu liposomes increased proliferation of human umbilical vein endothelial cells with raised VEGF and FGF-2 expression. For thymosin beta-4 it reported accelerated wound closure with increased collagen deposition and angiogenesis when applied as a hydrogel or a collagen-chitosan dressing, and stated that data on pain modulation by thymosin beta-4 are currently lacking.
- 09Review2026
Emerging Biologics in Lumbar Disc Degeneration: PRP, Stem Cell Therapy, and Pharmacotherapy in Mobility Restoration and Rehabilitation
Aabedi A, et al. · J Spine Res Surg · narrative review of emerging biologics for lumbar disc degeneration, covering platelet-rich plasma, stem cell therapy and peptide analogues
The review listed BPC-157, thymosin beta-4 and GHK-Cu together as peptide analogues with potential regenerative properties for musculoskeletal and intervertebral disc degeneration, and stated that the existing evidence for them remains predominantly preclinical with substantial safety and standardisation questions outstanding.
Side by side.
| TB-500 | GHK-Cu | |
|---|---|---|
| Evidence maturity | Early clinical | Early clinical |
| Studies cited here | 15 | 15 |
| Published 2023 or later | 8 | 10 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | Synthetic seven-residue fragment, Ac-LKKTETQ, marketed as an analogue of thymosin beta-4, a 43-amino-acid endogenous actin-sequestering peptide expressed across most tissues. | Copper(II) complex of glycyl-L-histidyl-L-lysine, a tripeptide that occurs endogenously in human plasma and binds copper with high affinity. It appears in cosmetic formulations under the name copper tripeptide-1. |
| Mechanism as described in the literature | Full-length thymosin beta-4 sequesters G-actin and promotes cell migration; the published biology covers endothelial migration and angiogenesis, epicardial activation in cardiac repair, anti-fibrotic activity and inflammation resolution, including a sulfoxide metabolite identified as a resolution signal. | Stimulation of fibroblast collagen and glycosaminoglycan synthesis at picomolar to nanomolar concentrations, copper binding and transport, and broad modulation of extracellular-matrix, antioxidant and inflammatory gene programmes reported in gene-expression work. |
| Size of the evidence base | A large preclinical literature spanning cardiac, corneal, dermal, pulmonary, renal, intestinal and endometrial models, almost all of it generated with full-length thymosin beta-4 or its recombinant form rather than with the marketed fragment. | Decades of in vitro and animal work, but a 2026 PRISMA systematic review searching from database inception to March 2026 identified only 20 eligible studies of GHK-Cu as a standalone aesthetic intervention, of which 18 were preclinical and 2 were randomised controlled trials. |
| Best-characterised finding | A 1999 rat full-thickness dermal wound study reporting increased re-epithelialisation and greater wound contraction relative to saline controls, with increased collagen deposition and angiogenesis, remains the foundational wound-healing result. | A 1988 fibroblast culture experiment reporting stimulation of collagen synthesis across a picomolar to nanomolar dose-response, independent of any change in cell number, remains the foundational result. |
| Human data | Completed randomised, double-blind, placebo-controlled trials in healthy volunteers, severe dry eye and chronic venous ulcers, plus a 2025 report covering both mice and patients with ST-segment elevation myocardial infarction. None addressed tendon, ligament or muscle injury, and all used full-length thymosin beta-4. | Present but thin and inconsistent. The two largest randomised trials of topical copper tripeptide, in venous stasis ulcers in 1992 and on CO2 laser-resurfaced skin in 2006, found no significant benefit on objective endpoints; a placebo-controlled trial of a 5-aminolevulinic acid and GHK complex in pattern hair loss reported increased hair count without differences in hair length or thickness. |
| Evidence maturity | Early clinical. Randomised human trials exist and are of reasonable design, but they were conducted with the full-length peptide and in indications unrelated to the musculoskeletal recovery for which the fragment is marketed. | Early clinical. Controlled human trials exist but the largest were negative on their objective endpoints, and most positive human reports come from uncontrolled studies of multi-ingredient formulations from which a GHK-Cu-specific effect cannot be isolated. |
| Regulatory and anti-doping status | No approved product for musculoskeletal recovery. Thymosin beta-4 and its derivatives, TB-500 among them, appear under growth factors and growth factor modulators on the World Anti-Doping Agency Prohibited List, and several recent publications are doping-detection methods rather than efficacy studies. | No approved drug in any jurisdiction. It circulates as a cosmetic ingredient rather than a medicine, and the 2026 orthopaedic and sports medicine reviews stated that no clinical data support its use for musculoskeletal conditions. |
| Basis of most marketing claims | Extrapolation from full-length thymosin beta-4 biology to the short Ac-LKKTETQ fragment that is actually sold. The fragment has very little independent pharmacology, and its equivalence to the full-length peptide is assumed rather than demonstrated. | Extrapolation from in vitro collagen and gene-expression data to topical cosmetic and repair outcomes that the controlled trials did not confirm. Skin permeation from cosmetic vehicles is not well characterised, and no dose-response for a topical anti-wrinkle effect has been established in humans. |
And what it does not.
Nothing published establishes how these two peptides compare, because no study has ever run them together. The nine publications that cover both are reviews from the past two years, and they converge on a shared reading rather than a ranking: promising preclinical signals, an absence of controlled human evidence for musculoskeletal or aesthetic repair, and no approved product for either. Read separately, the two literatures are asymmetric in different directions. Thymosin beta-4 has genuine randomised human trials, but they were run in dry eye, venous ulcers, healthy volunteers and cardiac ischemia, and they used the 43-residue peptide rather than the short fragment sold as TB-500. GHK-Cu has an endogenous role and a long mechanistic record in fibroblast culture, but its two largest randomised trials were negative on objective endpoints and a 2026 systematic review found only two randomised trials of it as a standalone aesthetic intervention. Neither compound has controlled human evidence for the repair claims that prompt the comparison in the first place.
Common questions.
- Has any experiment tested TB-500 and GHK-Cu against each other?
No. Searches of PubMed and Europe PMC located no study that administered both, and none that compared them in cell culture, in animals or in people. Every publication that engages both is a review that assigns them to a shared category of regenerative or wound-healing peptides and then describes each from its own separate literature. Any statement that one outperforms the other for tissue repair is an inference drawn across unrelated experiments rather than a reported comparative result.
- Why do reviews keep grouping these two peptides together?
Because both are described as acting on angiogenesis and extracellular-matrix remodelling, both are sold directly to consumers without an approved indication, and both surfaced in the same wave of clinical interest. Reviews published in 2026 in orthopaedic, sports medicine, pain medicine, gerontology and aesthetic journals list them alongside BPC-157 and growth hormone secretagogues for that reason. The grouping reflects how the compounds are marketed and encountered in practice, not a demonstrated similarity in pharmacology or in outcome.
- Which of the two has been studied in humans with a control group?
Both, but in different settings and with different results. Thymosin beta-4 has completed randomised, double-blind, placebo-controlled trials in healthy volunteers, in severe dry eye and in chronic venous leg ulcers. Copper tripeptide has been tested in a randomised evaluator-blinded venous stasis ulcer trial and in a randomised trial on CO2 laser-resurfaced skin, both of which found no significant advantage on objective endpoints. Neither compound has a controlled human trial in tendon, ligament or muscle injury.
- Does the research on thymosin beta-4 apply to the TB-500 fragment?
That equivalence is assumed rather than demonstrated. TB-500 is the synthetic Ac-LKKTETQ sequence, whereas the actin-binding region it derives from sits within a 43-amino-acid endogenous peptide. Nearly all published cardiac, corneal, dermal, pulmonary and anti-fibrotic biology was generated with the full-length peptide or its recombinant form. Very few papers address the fragment itself; one analytical study quantified TB-500 and its metabolites and screened them in wound-healing assays in vitro.
- What do the 2026 reviews say about safety for these compounds?
They report that rigorous human safety data are scarce. The sports medicine narrative review described a gray market of unapproved peptides operating largely outside regulatory oversight and noted the potential for serious harm, while identifying the placebo effect and social media amplification as mediators of perceived efficacy. The scoping review documented significant heterogeneity in route of administration across the published work. None of the reviews located long-term human safety data for either peptide in the uses for which they are promoted.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.